Faeth Therapeutics to Participate in Upcoming September Investor Conferences
Faeth Therapeutics to Participate in Upcoming September Investor Conferences
Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced that management will participate in the following upcoming investor conferences:
- Wells Fargo 21st Annual Healthcare Conference
Tuesday, September 8, 2026
1x1 investor meetings
Boston, MA - Citi Biopharma Back to School Summit
Wednesday, September 9, 2026
Fireside chat at 10:00 a.m. ET
New York, NY - Cantor Global Healthcare Conference 2026
Thursday, September 10, 2026
Fireside chat at 8:35 a.m. ET
New York, NY
Webcast Link - Morgan Stanley 24th Annual Global Healthcare Conference
Monday, September 14 & Wednesday, September 16, 2026
Fireside chat at 9:15 a.m. EDT on Wednesday
New York, NY
Webcast Link - Baird Global Healthcare Conference
Tuesday, September 15, 2026
Fireside chat at 10:15 a.m. ET
New York, NY - H.C. Wainwright 28th Annual Global Investment Conference
Wednesday, September 16, 2026
Fireside chat at 10:30 a.m. ET
New York, NY - Deutsche Bank 2026 Healthcare Summit
Thursday, September 17, 2026
1x1 investor meetings
New York, NY
Live webcasts of the Cantor and Morgan Stanley fireside chats can be accessed via the Events and Presentations section of the Faeth website at investors.faeththerapeutics.com. Replays will be available for approximately 90 days following the event.
About Faeth Therapeutics
Faeth Therapeutics, Inc. (Nasdaq: FTH) is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The Company’s lead program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer. Faeth was co-founded in 2019 by Anand Parikh and Oliver Maddocks, Ph.D., together with scientific founders Lewis Cantley, Ph.D., the discoverer of the PI3K pathway; Siddhartha Mukherjee, M.D., D.Phil.; Karen Vousden, Ph.D.; Scott Lowe, Ph.D.; and Greg Hannon, Ph.D. For more information, please visit www.faeththerapeutics.com and follow the Company on LinkedIn.
Investor Contact:
Matthew Biegler, SVP, Investor Relations
matt@faeththerapeutics.com
Media Contact:
Patrick Schmidt, Consort Partners
faeththerapeutics@consortpartners.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20260901235886/en/
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
5 Stocks to Sell for Tax-Loss Harvesting
33 Undervalued Stocks to Buy Before the Market Shifts Again
What’s Ahead for Stocks This Quarter—and Where to Invest
Ask the Analyst: What Is the Best Source for Low-Risk Tax-Free Income?
United States